Pietro Delfino
Overview
Explore the profile of Pietro Delfino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
322
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veghini L, Pasini D, Fang R, Delfino P, Filippini D, Neander C, et al.
Nat Commun
. 2024 Dec;
15(1):10534.
PMID: 39627211
Fibroblast heterogeneity is increasingly recognised across cancer conditions. Given their important contribution to disease progression, mapping fibroblasts' heterogeneity is critical to devise effective anti-cancer therapies. Cancer-associated fibroblasts (CAFs) represent the...
2.
Ciccocioppo R, De Marchi G, Zuliani V, Adamo A, Amodio A, Campagnola P, et al.
Gastro Hep Adv
. 2024 Aug;
1(3):437-444.
PMID: 39131669
Background & Aims: Type 1 autoimmune pancreatitis (AIP) is an IgG4-related disease whose diagnosis is challenging. The aim of this study was to investigate the diagnostic value of circulating total...
3.
Lupo F, Pezzini F, Pasini D, Fiorini E, Adamo A, Veghini L, et al.
Gut
. 2024 Apr;
73(8):1321-1335.
PMID: 38670629
Objective: The dysregulation of the axon guidance pathway is common in pancreatic ductal adenocarcinoma (PDAC), yet our understanding of its biological relevance is limited. Here, we investigated the functional role...
4.
DAgosto S, Fiorini E, Pezzini F, Delfino P, Simbolo M, Vicentini C, et al.
Front Endocrinol (Lausanne)
. 2023 Apr;
14:999792.
PMID: 37082125
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare and highly heterogeneous neoplasms whose incidence has markedly increased over the last decades. A grading system based on the tumor cells' proliferation index predicts...
5.
Erice O, Narayanan S, Feliu I, Entrialgo-Cadierno R, Malinova A, Vicentini C, et al.
Clin Cancer Res
. 2023 Jan;
29(6):1137-1154.
PMID: 36607777
Purpose: The identification of pancreatic ductal adenocarcinoma (PDAC) dysregulated genes may unveil novel molecular targets entering inhibitory strategies. Laminins are emerging as potential targets in PDAC given their role as...
6.
DAgosto S, Pezzini F, Veghini L, Delfino P, Fiorini C, Temgue Tane G, et al.
Oncogene
. 2022 Aug;
41(38):4371-4384.
PMID: 35963908
Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two major epithelial subtypes with distinct biology and clinical behaviours. Here, we aimed to clarify the role of FGFR1 and FGFR4...
7.
De Santis M, Gozzelino L, Margaria J, Costamagna A, Ratto E, Gulluni F, et al.
Gut
. 2022 May;
72(2):360-371.
PMID: 35623884
Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with limited therapeutic options. However, metabolic adaptation to the harsh PDAC environment can expose liabilities useful for therapy. Targeting the key...
8.
Carbone C, Piro G, Agostini A, Delfino P, De Sanctis F, Nasca V, et al.
J Immunother Cancer
. 2021 Sep;
9(9).
PMID: 34479922
Background: Complex tumor and immune microenvironment render pancreatic ductal adenocarcinoma (PDAC) resistant to immune checkpoint inhibitors (ICIs). Therefore, a strategy to convert the immune hostile into an immunopermissive tumor is...
9.
Di Nardo L, Pellegrini C, Di Stefani A, Ricci F, Fossati B, Del Regno L, et al.
Sci Rep
. 2021 Jun;
11(1):13206.
PMID: 34168209
A number of genes have been implicated in the pathogenesis of BCC in addition to the Hedgehog pathway, which is known to drive the initiation of this tumour. We performed...
10.
Gkountakos A, Delfino P, Lawlor R, Scarpa A, Corbo V, Bria E
Ther Adv Med Oncol
. 2021 Jun;
13:17588359211006947.
PMID: 34104224
The introduction of immune checkpoint inhibitor (ICI)-based therapy for non-oncogene addicted non-small cell lung cancer (NSCLC) has significantly transformed the treatment landscape of the disease. Inhibitors of the programmed cell...